The Da Zen technology is the result of a scientific collaboration among three institutions with a decades of cancer research expertise: Georgia State University, Emory University and Cedars Sinai Medical Center. Maged Henary spent years in collaboration with the late Dr. Leland W.K. Chung, renowned cancer researcher, to develop technologies that enable targeted delivery of anti-cancer drugs. The technology works using imaging dye-drug conjugates to improve diagnosis, detection and treatment of tumors.
Da Zen Theranostics Inc. has filed 10 exclusively licensed or proprietary patent protections, two which have been granted. Henary is the inventor of many of the core patents. Two of Da Zen’s drug conjugates, DZ-002 and DZ-003, are in the company’s research and development pipeline. The company will initiate clinical trials at Cedars Sinai Medical Center to test the effectiveness of DZ-002 as a treatment for cancer patients with solid tumors or lymphoma by the end of 2021.